LivaNova (LIVN) Set to Post Earnings on Wednesday

LivaNova (NASDAQ:LIVN) will likely be announcing its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect LivaNova to announce earnings of $1.06 per share and revenue of $381.10 million for the quarter. Investors can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 8:00 AM ET.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings results on Thursday, August 6th. The company reported $1.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.09 by $0.17. The business had revenue of $390.59 million during the quarter, compared to the consensus estimate of $380.50 million. During the same quarter in the previous year, the business posted $1.05 EPS. The company’s revenue for the quarter was up 10.8% on a year-over-year basis. On average, analysts expect LivaNova to post $3.78 EPS for the current fiscal year and $4.16 EPS for the next fiscal year.

LivaNova Stock Performance

Shares of LIVN stock opened at $80.38 on Wednesday. LivaNova has a twelve month low of $48.82 and a twelve month high of $85.76. The business has a fifty day simple moving average of $78.45 and a 200 day simple moving average of $72.66.

Analyst Ratings Changes

A number of research firms have issued reports on LIVN. Zacks Research cut LivaNova from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 19th. Barclays raised shares of LivaNova to a “strong-buy” rating in a report on Wednesday, October 7th. Needham & Company LLC raised their price target on shares of LivaNova from $81.00 to $93.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Freedom Capital raised shares of LivaNova to a “hold” rating in a report on Tuesday, June 30th. Finally, Weiss Ratings raised shares of LivaNova from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, LivaNova presently has a consensus rating of “Moderate Buy” and a consensus price target of $87.75.

Insider Buying and Selling at LivaNova

In other news, Director Francesco Bianchi sold 3,500 shares of LivaNova stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $78.01, for a total transaction of $273,035.00. Following the sale, the director directly owned 4,434 shares of the company’s stock, valued at approximately $345,896.34. This trade represents a 44.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Brooke Story sold 2,300 shares of the business’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $81.42, for a total value of $187,266.00. Following the sale, the director owned 7,488 shares in the company, valued at approximately $609,672.96. This trade represents a 23.50% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 7,450 shares of company stock worth $591,839. 0.35% of the stock is currently owned by company insiders.

LivaNova Company Profile

LivaNova PLC (NASDAQ: LIVN) is a medical technology company that develops and manufactures devices and therapies for patients with neurological and cardiovascular conditions. Its products are used by hospitals, physicians and other healthcare providers in markets around the world.

The company’s Neuromodulation business is best known for VNS Therapy, which uses an implanted device to deliver electrical stimulation to the vagus nerve. The therapy is used primarily for drug-resistant epilepsy and treatment-resistant depression, subject to applicable regulatory approvals.